MIB-626

Phase 2Small molecule

MMetro International Biotech, LLC

MIB-626 is one of 117 small molecule programs targeting Down syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

116

Competitors

Pipeline

Status by Indication[3][1]

Indication

Down SyndromeActive, not recruiting

Alzheimer DiseaseCompleted

COVID-19Active, not recruiting

Down Syndrome (DS)Not yet recruiting

Coronary Artery Bypass GraftRecruiting

AtaxiaActive, not recruiting

Down SyndromePhase 1

Active, not recruiting

Alzheimer DiseasePreclinical

Completed

COVID-19Phase 2

Active, not recruiting

Down Syndrome (DS)Phase 1

Not yet recruiting

Coronary Artery Bypass GraftPhase 2

Recruiting

AtaxiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

MIB-626

MMetro International Biotech, LLC

Phase 2

1 2

Tricor

JJagotec

Preclinical

1 3

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 4

SARS-COV-2 VACCINE

Moderna

Preclinical

2 5

Statin

Bristol-Myers Squibb

Preclinical

1 6

Selenium

SSWOG Cancer Research Network

Preclinical

1 7

Standard Preparation

LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Preclinical

1 8

Hydroxychloroquine Pill

UUniversity of Calgary

Preclinical

2 9

Disease-Modifying Anti-Rheumatic Drugs

Roche

Preclinical

1 10

Other Tkis

Bayer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1Not yet recruiting

Down Syndrome (DS)

NCT07278492

Q1 2029

Phase 2Recruiting

Coronary Artery Bypass Graft

NCT07013591

Clinical

Trials by Indication[1]

Ataxia1 trial

NAD+ Precursor Supplementation in Friedreich's Ataxia

Completed·MMetro International Biotech, LLC·Phase 2·NCT04817111·7 enrolled

COVID-191 trial

Phase 2a MIB-626 vs. Placebo COVID-19

Completed·MMetro International Biotech, LLC·Phase 2·NCT05038488·42 enrolled

Alzheimer disease1 trial

A Proof of Concept Trial of a Sirtuin-NAD Activator in Alzheimer's Disease

Completed·BBrigham and Women's Hospital·Preclinical·NCT05040321·22 enrolled

Coronary Artery Bypass Graft1 trial

Randomized Clinical Trial of β Nicotinamide Mononucleotide in Patients Undergoing CABG Surgery

Recruiting·BBrigham and Women's Hospital·Phase 2·NCT07013591·90 enrolled

Down Syndrome (DS)1 trial

Nicotinamide Adenine Dinucleotide Augmentation to Prevent or Reverse the Progression of Alzheimer's Disease in People With Down Syndrome

Not yet recruiting·BBrigham and Women's Hospital·Phase 1·NCT07278492·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for MIB-626. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MIB-626 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MIB-626. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Metro International Biotech, LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMetro International Biotech, LLC

MIB-626

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q1 2029

Trials by Indication[1]

Ataxia1 trial

COVID-191 trial

Alzheimer disease1 trial

Coronary Artery Bypass Graft1 trial

Down Syndrome (DS)1 trial

References

Drug Info

Quick Facts

Related News